(Group 3)

For definition of Groups, see Preamble Evaluation.

VOL.: 66 (1996) (p. 157)
CAS No.: 26308-28-1

Chem. Abstr. Name: 1-Ethyl-4,6-dihydro-3-methyl-8-phenylpyrazolo[4,3-e][1,4]diazepin-5(1H)-one

5. Summary of Data Reported and Evaluation

5.1 Exposure data

Ripazepam is a pyrazolodiazepine with anxiolytic properties which has never been marketed for human use.

5.2 Human carcinogenicity data

No data were available to the Working Group.

5.3 Animal carcinogenicity data

Ripazepam was tested for carcinogenicity in one experiment in mice and in one experiment in rats by oral administration in the diet. An increased incidence of benign liver tumours was found in male mice. No increase in the incidence of tumours was found in female mice or in rats of either sex.

5.4 Other relevant data

No data were available to the Working Group on the metabolism, toxicity, reproductive or genetic and related effects of ripazepam.

5.5 Evaluation

There is inadequate evidence in humans for the carcinogenicity of ripazepam. There is limited evidence in experimental animals for the carcinogenicity of ripazepam.

Overall evaluation

Ripazepam is not classifiable as to its carcinogenicity to humans (Group 3).

For definition of the italicized terms, see Preamble Evaluation


Last updated 05/22/97

    See Also:
       Toxicological Abbreviations